Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2018 | Motility-associated microglial proteins in Alzheimer’s disease and after Aβ42 immunotherapy

In recent studies, genetic results have shown that microglial proteins are important in the onset of Alzheimer’s disease. Now, speaking at the Alzheimer’s Research UK (ARUK) Conference 2018, held in London, UK, Delphine Boche, PhD, from the University of Southampton, Southampton, UK, presents the findings of her group’s work on the role of motility-associated microglial proteins in Alzheimer’s disease. Interestingly, the post-mortem brain tissue of patients who took part in the halted Aβ42 immunotherapy clinical trial were also studied. Here, Prof. Boche explains the interesting nature of microglia in the brain and discusses the aims, methods and results of the study.